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Abstract: Despite recent genetic advances and numerous ongoing therapeutic trials, malignant
melanoma remains fatal, and prognostic factors as well as more efficient treatments are needed.
The development of such research strongly depends on the availability of appropriate models
recapitulating all the features of human melanoma. The concept of comparative oncology, with the
use of spontaneous canine models has recently acquired a unique value as a translational model.
Canine malignant melanomas are naturally occurring cancers presenting striking homologies with
human melanomas. As for many other cancers, dogs present surprising breed predispositions and
higher frequency of certain subtypes per breed. Oral melanomas, which are much more frequent
and highly severe in dogs and cutaneous melanomas with severe digital forms or uveal subtypes
are subtypes presenting relevant homologies with their human counterparts, thus constituting
close models for these human melanoma subtypes. This review addresses how canine and human
melanoma subtypes compare based on their epidemiological, clinical, histological, and genetic
characteristics, and how comparative oncology approaches can provide insights into rare and poorly
characterized melanoma subtypes in humans that are frequent and breed-specific in dogs. We propose
canine malignant melanomas as models for rare non-UV-induced human melanomas, especially
mucosal melanomas. Naturally affected dogs offer the opportunity to decipher the genetics at both
germline and somatic levels and to explore therapeutic options, with the dog entering preclinical
trials as human patients, benefiting both dogs and humans.
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1. Introduction
Human malignant melanoma is a highly heterogeneous cancer that affects numerous anatomical
sites with different clinical behaviours. It originates from melanocytes, which are dendritic cells
located in epithelia such as skin or mucosa, but also in the eye or internal organs, thus defining major
subtypes with specific anatomic locations and pathogenesis. The major subtypes include cutaneous
(UV-induced and non-UV-induced types), acral, mucosal, and ocular melanomas. Epidemiology,
UV-radiation status, histopathological features, genetics, prognosis, and outcomes vary considerably
between these subtypes.
Cutaneous melanomas account for approximately 75% of skin cancer deaths [1,2], and their
incidence is rising among populations of European descent, with 80,000 cases per year in the USA [3].
The current World Health Organization (WHO) classification for cutaneous melanoma is based
on morphologic aspects of the early growth phase and the body site of the primary melanoma, to
distinguish four main types: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM),
nodular melanoma (NM), and acral lentiginous melanoma (ALM) [1–5]. Chronic and intermittent
ultraviolet exposures are a major cause of melanoma development in sun-exposed skin. UV-induced
melanoma with cumulative sun-induced damage (CSD) and non-CSD melanoma are the most common
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types in peoples of European descent and occur at around 60 and 40 years of age, respectively [1].
Another type of melanoma affecting non-sun-exposed or specific sites is acral melanoma, with locations
on the palms of the hands, soles of the feet, and the nail apparatus, which occurs at similar incidences
across all world populations [6]. Additional rare categories of melanomas present distinct clinical,
epidemiological, and histopathological features, such as desmoplastic melanoma, spitzoid melanoma,
blue nevus-like melanoma, melanoma in giant congenital nevus, and other types arising from dermal
melanocytes (nevus of Ota, nevus of Ito) [1]. Even if the major part of cutaneous melanoma is diagnosed
at an early stage, approximately 10% of melanoma cases are unresectable or already metastatic at
diagnosis [7]. For those latter patients, the prognosis is poor, with a 5 year survival rate of around
12% [8], whereas it is around 90% for cutaneous melanomas of all stages [9,10]. Acral subtypes carry
the worst prognosis among cutaneous melanomas, with a 5 year survival rate of around 80% [11].
The impact of other subtypes on prognosis is not known [5].
Mucosal melanomas originate from melanocytes within mucosal epithelia and constitute a rare
clinical entity representing 0.8–3.7% of all melanomas [12], with an incidence of 800 cases per year in
the USA [3]. Although rare in the general population, these account for 9–22% of melanoma cases
in Asian and black populations where cutaneous melanoma is less common [12] and occur around
the age of 60–70 [3]. They exhibit a pathogenic mechanism different from cutaneous subtypes and a
much worse prognosis. They can originate from the anogenital regions, oropharynx and paranasal
sinuses, as well as the conjunctiva (head and neck localisations), and can also arise from parotid glands,
oesophagus, and the middle ear [13]. Local and/or distant metastasis to lungs and liver occur in 50% of
cases with head and neck melanoma [3]. Mucosal melanomas carry a poor prognosis, with a 5 year
survival rate between 25% and 33%, according to disease stage and location [3,14].
Uveal melanoma is the most common intraocular human cancer and accounts for approximately
5% of all melanoma in the United States [1], occurring at around 60 years of age [15]. The incidence of
uveal melanoma is stable with 2500 new cases per year in the USA [3]. The most frequent sites are the
choroid and the ciliary body. Although uveal melanoma is rare, the disease is still lethal. Almost half
of patients with effective primary therapy will develop metastases [16], and these patients have a poor
prognosis, with a median survival time ranging from 4 to 15 months [17].
2. Comparative Oncology, Model Specificities
Melanomas are generally aggressive, with a high metastatic propensity toward several organs
including lungs, bones, liver, and the central nervous system. Even though the development of targeted
therapy and immunotherapy has improved outcomes, there is still a lack of knowledge to enable the
development of efficient treatments with sustainable response and to provide clues to the mechanisms
of resistance. Despite numerous efforts to better understand the genetics and physiopathology of
melanomas, previous studies mainly focused on cutaneous melanoma and often considered different
melanoma types as a single disease entity. Fortunately, recent published data in the discipline has
highlighted and precisely described molecular specificities based on the different melanoma subtypes.
The discovery of genetic alterations has led to the development of targeted therapies, such as
tyrosine kinase inhibitors or BRAF inhibitors, new therapeutic options, and stratification of patients.
However, melanoma research could certainly benefit from additional models to those currently used.
Indeed, the popular mouse model used over the last decades in the study of cancer has revealed
some limits: patient-derived xenograft mouse models lack a fully functional immune system, and
genetically engineered mouse models are expensive and do not carry the same mutagenic load and
genetic background as human cancers [18]. It is also now recognized that mice were not as efficient
as expected to objectify drug response in Phase III clinical trials. Researchers then became more and
more interested in naturally occurring cancers in pet animals, because they are immuno-competent
individuals sharing our environment, and the natural history of cancer in animals occurs in a generally
shorter period than in humans. Thus, many cancers in pet dogs show similar features to their human
counterparts, including clinical and histological appearance, biological behaviour, tumor genetics,
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molecular pathways and targets, and response to therapies [19–22]. Most recent genetic analyses of
cancer in pet dogs has shown their usefulness in specifically identifying key somatic genes and relevant
mutational mechanisms [22–30]. Their advantages require no further demonstration and, considering
the ethical constraints in the use of experimental models in respect of the 3R rules (Replace, Refine,
Reduce), the use of naturally affected pets in their environment and followed-up by their veterinarians
should be encouraged in comparative oncology programs.
For melanomas, obvious unmet needs remain to better manage, treat, and prevent this disease,
considering their numerous specific subtypes. To this end, recent reviews have demonstrated the
strength of spontaneous canine melanomas as relevant genetic and therapeutic models for specific
human melanoma subtypes [18,21,31–35].
3. Canine Melanomas
Melanocytic tumors are quite common in the dog, and most of them are malignant [34,36–40].
Of over 2350 cases of melanocytic tumors, 70% were malignant melanomas and 30% benign tumors
(called melanocytomas) [34]. Melanoma represents 7% of all malignant tumors in dogs [37], and the
most frequent location is the oral cavity, mimicking human mucosal melanomas [32–34]. Canine
melanomas also occur in the haired skin, nail bed, footpad, eye (Figure 1), gastro-intestinal tract,
central nervous system, or muco-cutaneous junction [37,38,41], and it is well known that prognosis
greatly depends on tumor location (Figures 2 and 3); oral melanomas presenting the worse prognosis
with a median survival time (MST) of 6 months, whereas MST was not reached in cutaneous forms.
Digital forms seem to have intermediate prognosis, with an MST of 11.8 months [30,32–37]. Melanoma
is a tumor of older dogs, with no sex predilection, but some breeds are more prone to develop a
specific melanoma subtype [18,34,42–44]. Contrary to human cutaneous melanoma, which are the
most frequent and for which UV light exposure and fair skin are known to be important etiological
factors, canine melanoma etiology is not known. However, UV light exposure is not thought to be
an etiological factor. Indeed, dog skin is covered with fur, and dogs with dark coat colours are more
prone to develop melanoma. Most canine melanomas arise from the dermis, but melanocytes and
melanocyte precursors in the dog skin are located in both layers: in the basal layer of the epidermis
and in the dermis. In dogs, of course, the presence of melanocytes in the numerous hair follicles of the
dermis is to be taken into consideration, but is not fully explored so far.
A major interest with dog melanomas is that specific breeds are at higher risk to develop specific
melanomas subtypes, and thus the breed is an etiological factor underlying genetic predisposition
differing from breed to breed. Altogether, striking homologies have been observed between canine
melanomas and human non-UV-induced melanomas; mostly oral and non-UV-induced cutaneous
melanomas, like acral melanomas, also observed in people with a dark phototype [11,12].
Concerning histopathology, there are also striking homologies. Using a comparative approach, we
previously reviewed 153 melanocytic tumors from oral, cutaneous, and ocular locations, and found four
categories resembling human histological subtypes [34]: animal-type melanoma, melanoma simulating
nevus, melanoma with epithelioid cells, and melanoma with composite cells (Figure 1) [32–34,39,41,42].
Thus, canine melanomas constitute relevant spontaneous models for human mucosal, acral, uveal,
and non-UV-induced cutaneous melanomas.
In this review, we attempt to provide the key contributions from canine melanomas in the context
of comparative oncology. We present state-of-the-art epidemiology, pathology, genetics, and therapy of
canine melanomas based on the different subtypes: mucosal, cutaneous, digital, and uveal melanomas.
Genes 2019, 10, 501 4 of 20
Genes 2019, 10, x FOR PEER REVIEW 4 of 21 
 
 
Figure 1. Histopathological aspects of human (left) and dog (right) melanoma 
morphological subtypes. Hematoxylin–Eosin–Safranin (HES) staining of formalin-fixed 
and paraffin-embedded biopsies. Photo credit: B. Vergier and J. Abadie. (A) “Animal type”: 
sheets or bundles of highly pigmented large epithelioid to spindle-shaped neoplasic 
melanocytes; (B) “Simulating (congenital or cellular blue) naevi type”: sheets with a high 
cellular density of small oval to spindle cells with a small central nucleus containing one to 
several small nucleoli; (C) “Epithelioid type”: large round to polygonal epithelioid cells 
with a high amount of variably pigmented cytoplasm and a large nucleus. 
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Figure 1. Histopathological aspects of human (left) and dog (right) melanoma morphological subtypes.
Hematoxylin–Eosin–Safranin (HES) staining of formalin-fixed and paraffin-embedded biopsies. Photo
credit: B. Vergier and J. Abadie. (A) “Animal type”: sheets or bundles of highly pigmented large
epithelioid to spindle-shaped neoplasic melanocytes; (B) “Simulating (congenital or cellular blue) naevi
type”: sheets with a high cellular density of small oval to spindle cells with a small central nucleus
containing one to several small nucleoli; (C) “Epithelioid type”: large round to polygonal epithelioid
cells with a high amount of variably pigmented cytoplasm and a large nucleus.
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Figure 3. Kaplan Meier survival curve of 335 dogs with malignant melanoma. Oral (green line), digital
(blue line), and cutaneous (red line) melanomas have significantly different prognosis (p < 0.0001,
log-rank test). Oral melanomas have the worse prognosis with a MST (median survival time) of six
months, whereas survival times were highest in cutaneous forms (MST not reached). Digital forms
seem to have intermediate prognosis with an MST of 11.8 months (Prouteau et al., in preparation [39]).
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4. Canine Mucosal Melanoma
4.1. Epidemiology
Canine oral melanoma is the most common type of mucosal melanoma in dogs and the most
common oral malignancy in this species. It occurs mostly on the gingiva, but also on the lips, tongue,
tonsils, palate, and oropharynx [34,37,38,41,42]. Mean age at diagnosis is around 10–11 years of age,
and several studies have identified breeds more prone to develop this oral form, such as poodles,
golden and Labrador retrievers, Rottweilers, Yorkshire terrier, cocker spaniels, chow-chows, Scottish
terriers, and daschunds (Figure 4A) [34,38–40,42–44]. Other mucosal sites comprise the anorectal
region [45], intestines [46], and nasal cavity, but these entities are very rare in dogs [47–49].
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Figure 4. (A) Breed distribution in a study of 247 canine oral melanomas. Five breeds represent 50% of
cases, illustrating the breed predisposition (Prouteau et al., in preparation [39]). (B) Pictures of canine
oral melanoma involving the gingiva; that can be pigmented (on the top left) or amelanotic (on the top
right). Pictures of human mucosal melanoma (pigmented tumors) arising on the gingiva of the oral
cavity. Photo credit: P. De Fornel, A. Dupuy and T. Jouary.
4.2. Clinical Signs and Biological Behaviour
The clinical presentation of canine melanomas varies considerably; it can consist of small
brown-to-black masses, but can also appear as large, flat, and/or wrinkled masses, highly to slightly
pigmented or amelanic (Figure 4B). Clinical signs of oral melanoma include dysphagia, halitosis,
ptyalism, bleeding, and occasionally fracture of the mandible in case of bone invasion [37,38]. This is
an aggressive tumor with a local invasiveness and a high metastatic propensity to regional lymph
nodes and lungs [32,33,35]. Recent studies suggest that the prevalence of pulmonary metastasis in
canine oral melanoma is around 17%–51%, highlighting the aggressiveness of this disease [50–52].
Some cases of intranasal or anal sac melanoma have been reported, but these are rare and prognosis is
poor. In a recent study, 12 anal sac melanoma cases were treated with surgery most of the time with or
without adjuvant chemotherapy, and 10/12 dogs experienced local recurrence or metastasis to regional
lymph nodes, penis, or lungs [45].
4.3. Histopathology
Previous histopathological characterization of canine oral melanoma showed several major cell
types, such as epithelioid cells, spindle cells, mixed types containing both patterns, and less frequent
balloon or signet ring cells [36,53]. These histological types were not found to be prognostic [54].
One third of canine melanomas are amelanotic, and immunohistochemistry is sometimes needed to
differentiate them from carcinomas or sarcomas [31]. Recently, oral melanoma cases with an infrequent
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cancer-related death rate were characterized by a limited size, an intense pigmentation, a low mitotic
index, and a lack of cellular atypia, representing up to 10% of oral melanomas [33,55].
4.4. Treatment
The first line and most effective local treatment is surgical excision [38]. Oral melanomas which
invade or are in proximity to the bones are treated with partial mandibulectomy/maxillectomy, and
these interventions, while highly invasive, are usually well tolerated [51,52,56–58].
Radiation therapy is generally used as a palliative treatment for unresectable tumors [59], as a
neoadjuvant therapy before surgery, or as an adjuvant therapy when surgical margins are incomplete.
The reported ranges of partial and complete responses to radiation therapy are 25–44% and 41–69%,
respectively, yielding overall response rates of 82% to 94%, according to the studies [50,60–63]. In spite
of the evident radiosentivity of oral melanoma, there is no standard treatment indicating the number
of fractions and dose per fraction.
The aggressiveness and high metastatic propensity of canine oral melanoma make systemic
therapies very interesting to extend survival and slow or prevent metastases occurrence.
Several studies used systemic chemotherapy with carboplatin, cisplatin, melphalan, or
temozolomide [40,50,60,62,64–66] and showed conflicting results, but the majority of them concluded
that there were no differences in terms of survival time or time to progression compared with surgery
or radiation therapy.
Thirteen years ago, Bergman et al. developed a xenogenic human tyrosinase DNA vaccine for
dogs with oral melanoma, and a Phase I trial demonstrated that some dogs with advanced stage disease
(presence of distant metastases) experienced long-term survival [43,67]. Since then, this DNA vaccine
has been licensed by USDA (United States Department of Agriculture, Oncept TM), but further studies
evaluating its efficacy reported controversial results (reviewed in Atherton et al. (2016)) [43,68–70].
More recent studies showed extended survival times, but the heterogeneity of inclusion criteria makes
interpretation difficult [71–73]; in particular, a clinical response in 8/13 dogs with macroscopic tumors
was reported by Verganti et al. (2017) [73].
4.5. Prognosis
In canine melanomas, location is the major prognostic factor (Figure 2). Indeed, the oral subtype
carries the worse prognosis, with reported median survival times (MST) between 3 months and
24 months, according to the stage (modified WHO staging system from I to IV, with tumor size, lymph
node involvement, and metastases) and treatment [33,34,45,46,52,59,60,65,68–70]. The MST for dogs
with surgically resected stage II–III oral melanoma is only 3–12 months, with an estimated one year
survival rate of only 20% [70,74]. Even with a radical surgical excision, recurrence rates are still
high (22–48%) [50–52,56,57], underlying the need for efficient systemic therapies. Regardless of the
clinical stage, a threshold for Ki67 above 19.5 % predicted melanoma-related death within a year of
diagnosis [75]. Among other pathological criteria, low pigmentation, a high nuclear atypia score, and a
high mitotic index (>4 mitosis figures over ten fields) are linked to a poor outcome [33,37]. Most cases
of oral melanoma carry a very poor prognosis, however, a small proportion of well-differentiated,
slowly growing tumors has been described [52,55]. Such entities also exist in humans, for who the
prognosis criteria are mainly based on histopathological features, ulceration, and Breslow parameters,
but they do not constitute a given subtype.
4.6. Genetic Features and Comparative Aspects
Canine mucosal melanomas have been recently studied at the molecular level. Obviously
different from human cutaneous melanomas, the main genetic alterations do resemble that of human
mucosal melanomas.
First analysed through candidate gene approaches, mutations were reported on NRAS, at the
same hotspots as in human cancers (NRASQ61), and on PTEN, but not on BRAFV600 and KIT [34,76,77].
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Then, using array-comparative genomic hybridization (aCGH), recurrent deletions including CDKN2A
and PTEN tumor suppressor genes were described [78]. Substantial recurrent gains of chromosomes,
notably, CFA13 (Canis familiaris) and CFA17 (involving at least KIT and MYC oncogenes) were identified,
the most recurrent aberrations being a complex copy number profile on CFA30 with alternate losses and
gains and CFA 10 rearrangements encompassing the oncogenes MDM2 and CDK4 [78]. Most recent
findings from NGS methods on canine oral melanoma of several breeds, through whole genome
sequencing of five cases and targeted sequencing of 26 cases [29], exome sequencing of 65 FFPE
(formalin fixed and paraffin embedded) cases [30], and exome sequencing of 69 cases [79] showed
concordant results: mutations on NRAS, KRAS, occurred in 10–20% of cases, PTEN and TP53 in 10 %
and 8–28% of cases, respectively [29,30].
Importantly, canine oral melanoma presents numerous copy number alterations (CNA) and a
relatively low single nucleotide variation (SNV) rate with general non-UV mutation signatures, as first
shown in human mucosal melanomas [9]. The “chromotripsis like” profile on CFA30 was reported
in canine oral melanomas concerning 60% of affected dogs and corresponds to the HSA15 alteration
observed in human cases [80]. SNV detected in canine oral melanomas are also present in human
mucosal melanoma [30,81,82], with exceptions for SF3B1, ATRX, and SPRED1 mutations, that were
not identified in dogs [30,83]. Conversely, recurrently altered genes such as PTPRJ, suggested to be
inactivated in 23% of canine mucosal melanomas are not yet found in human cancers [29]. Indeed, in
human mucosal melanoma cases, mutation profiles seem to vary slightly according to the mucosal
anatomical site. For example, NRAS mutations are mostly seen in sinonasal forms [30,84], whereas
mutations in KIT, NF1, and SFB31 are recurrent in anogenital forms [30,85]. Further studies in canine
oral melanomas should shed some light on these aspects, revealing recurrent mutations with strong
effect in specific locations and specific breeds, reflecting different genetic backgrounds that are easiest to
investigate in dog breeds. These data were very recently enriched by comparative expression profiling
of 28 cases of oral malignant melanoma, comparing metastatic/primary situations [86].
In both species, the MAPK and PI3K pathways are involved in mucosal melanoma formation and
progression [29–31,82,85,87]. All of these data suggest that canine and human mucosal melanomas
share similarities and that dog could be a good preclinical model for this rare human cancer.
The search for predisposing mutations has not been extensively investigated in canine melanomas,
however, recent analyses of exome sequence data have been performed in human, dog, and horse
mucosal melanomas [30]. The authors looked for pathogenic germline variants already established in
human melanoma susceptibility genes [88], including CDKN2A, BAP1, POT1, and TP53, based on their
orthologs in the canine genome, but to date none have been identified in canine oral melanoma.
5. Canine Cutaneous Melanoma
Malignant melanoma is a relatively common cancer in dogs and accounts for 9–20% of skin tumors
in that species [89]. Interestingly, tumors in cutaneous locations are often benign; 60% of them are
benign melanocytomas [34,90], according to pathological criteria, such as nuclear atypias and mitotic
index <3 mitoses over ten fields [90,91].
In contrast to human cutaneous melanoma for which UV-light exposure is a major etiologic factor,
dogs are naturally protected against sun exposure by their hair. Furthermore, black-coated breeds with
pigmented skin are at increased risk, as is the case with schnauzers, Scottish terriers, poodles, golden
retrievers, dachshunds, cocker spaniels and chow-chows [18,34,42–44].
Melanocytic neoplasms in dogs are usually dermal, arising on hair-bearing skin of the head, ears,
neck, trunk, and limbs [32–34]. Whereas melanocytomas are usually solitary, small, pigmented, firm,
and freely moveable over deeper structures, malignant melanomas tend to be fast-growing tumors,
often ulcerated and pigmented (Figure 5) [92].
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Usually, surgical resection is curative [32–34,87,89], although some pathological characteristics,
such as a mitotic index ≥3 over ten fields (otf) the presence of ≥20 nuclear atypia, a Ki67 index >15%,
ulceration, lymphatic invasion, and tumors extending beyond the dermis, have a negative influence on
prognosis [33,35,37,90,91]. More recently, Silvestri et al. showed that Breslow thickness is significantly
associated with histological malignancy, clinical outcome, and presence of recurrence/metastasis [93].
Cutaneous melanoma has a relatively benign behavior in dogs. Recent studies, evaluating
outcomes after surgical excision, showed that the MST was 1363 days and not reached with 77%–88%
of dogs alive at 1 year and 54% alive at 2 years [36,39,40,93,94] (Figure 2). In the series of 87 dogs
(Laver et al., 2018), 12% of dogs had lymph node metastases and 3.7% had pulmonary metastases at
diagnosis. Interestingly, the authors proposed that a mitotic index threshold of 20 mitosis figures over
ten fields accurately predicts the outcome. It appears that local resection alone is sufficient for most
localized canine cutaneous melanomas, and the clinical benefit of adjuvant therapies like chemotherapy
or DNA vaccines has not been shown [40,94].
Genetic Fe tures and Comparative Aspects
The data available on somatic alterations are based on few cases of canine cutaneous melanoma.
First, aCGH experiments on five tumors identified copy number alterations such as gains on the CFA 20
and losses on the CFA 6 and 18 [78]. A candidate gene approach with 20 cutaneous melanomas found
no variant in BRAF, NRAS, PTEN, KIT, GNAQ, and CDK4 [34]. Hendricks et al., (2018) provided genetic
results of two cutaneous melanoma cases: an NRAS mutation and a translocation in chromosome 10
(region 10–12 Mbases) for one case (Whole Genome Sequencing) and KRAS, TP53, and KIT mutations
with amplification of chromosome 30 (region 16,164778 -16,525074 Mbases) for the other case (targeted
sequencing) [29]. These preliminary data, together with the fact that canine cutaneous melanocytic
tumors are most often benign and not linked to UV-light exposure, confirm that these canine cutaneous
forms arise from a distinct mechanism, different from that of most human cutaneous melanomas.
Indeed, human UV-induced cutaneous melanomas carry a clear UV-mutational signature and an
important mutation burden with recurrent mutated genes such as BRAF, NRAS, HRAS, NF1, CDKN2A,
TP53, and PTEN and the recently identified genes, such as PPP6C and RAC1 [80,82,95]. However, the
identification of genetic alterations in canine cutaneous tumors should provide interesting results and
new data for the less investigated non-UV-induced subtypes of melanomas in humans, such as acral
melanoma, or rare categories of dermal melanomas [1].
In terms of research on human cutaneous melanoma predisposition, numerous GWAS (Genome
Wide Association Study) have been performed on large worldwide cohorts of patients and controls over
the last 10 years, which has led to the identification of over 20 genome-wide significant melanoma risk
regions [30,95–97]. While several dog breeds are predisposed to cutaneous melanoma, germline variants
are worth exploring to inform the genetics of the rare non-UV-induced subtypes of human melanomas.
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6. Canine Digital Melanoma
Melanoma is the second most common canine digital tumor after squamous cell carcinoma and
accounts for 15%–17% of neoplasias of the digits [98,99]. It arises on the skin digits, footpad, or nail
bed and mimics human acral melanoma (plantar surface of the foot, palms of hands, and fingers)
(Figure 6). Previous studies showed that between 49–86% of canine melanocytic tumors of the digits
were malignant and that all nail bed melanocytic tumors were malignant [34,90,91]. It is a tumor of old
dogs, occurring around 10 years of age [98]; some breeds are over-represented like Scottish terrier [98],
schnauzer, Beauce shepherds, and Rottweilers [34,99].
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These melanomas have a biological behaviour intermediate between oral and cutaneous
melanomas (Figure 3). They are locally aggressive, with bone lysis occurring in 40–58% of cases [99,100]
and have a high metastatic propensity, with regional or distant pulmonary metastasis in 30% to 40%
of cases at presentation [99,101]. Without regional or distant metastases, the first-line treatment is
amputation of the digit; then, the MST is 12 months, with 42–57% of dogs alive at 1 year and 11–13%
alive at 2 years [38,98,99,101]. These data confirm the aggressiveness of digital melanomas, their poor
prognosis, and the need for adjuvant therapy. A few studies have reported that chemotherapy does
not lead to a survival benefit [40]; xenogeneic DNA vaccine is safe and resulted in an MST of 476 days,
but still 50% of dogs treated developed metastases during the course of treatment [100].
Genetic Features and Comparative Aspects
To date, only 3 canine acral tumors have been studied and all harboured RAS mutations (2 KRAS
and 1 NRAS), and CNA involving CFA30 was found in one case [29]. In humans, a series of 35 samples
of acral melanomas [82] have b en shown to present a c mplex c y number alteration profile ore
similar to mucosal than cutaneous melanomas [9,82,102]. Significantly mut ted genes such as BRAF,
NRAS and NF1 have been identified in half of the cases [82].
Concerning germline variants, there are n data available in dogs or humans, wher as
predispositions are known in black-coated dogs from sever l terrier breeds, and their genetic analyses
would greatly inform the rare and s vere corresponding human su types.
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7. Canine Uveal Melanoma
Melanocytic tumors are the most common primary ocular neoplasms in dogs. They can be
limbal or epibulbar, but the most common site is the anterior uvea (iris and ciliary body) [103–105].
The biological behavior of these ocular melanomas depends on their location, with uveal melanoma
being the most frequent and aggressive [31]. In contrast to humans, primary choroidal melanoma is
rare in dogs [32,33]. Between 15 and 29% of canine intraocular melanocytic tumors are histologically
malignant [34,37,105], and they are defined by their cytologic abnormalities and a mitotic index
superior to four mitosis figures over ten fields [103,106]. More recently, a study tended to discriminate
between benign (“melanocytoma-like melanoma”) and malignant uveal melanocytic cases based on
morphological criteria such as smaller tumor size, high degree of pigmentation, and low mitotic
activity [106]. At examination, the first abnormality commonly observed is a dark-pigmented mass
in the anterior segment of the eye [101], but melanoma can be amelanotic in rare cases (Figure 7).
Associated clinical signs include iris thickening, irregular pupil with blindness and ocular pain, or
secondary symptoms such as keratitis, uveitis, or glaucoma [37,103,104].
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Only 4% to 8% of malignant uveal melanomas metastasize to lungs and liver, generally
within 3 mon hs following enucleation, co sistent with what it is seen in localized human iris
mela omas [103,107,108]. A few cases with la e metastase have been reported in dogs, occurring
more than 1.5 years after initial diagnosi [109,110]. Canine int aocular melanomas are treated with
enuclea ion if there is c ncern about malig ancy or complications. In order to preserv the ye and
vision, local resecti n ay be performed on isolated primary masses involving only the iris r a
portion of the ciliary b dy, but long-term results are oft n unsatisfactory. Othe available reatments
for uveal melanoma include la er the apy, which holds promise fo the p lliation or potential cure
while preserving vision [38].
The prognosis for dogs with histologically benign uveal melanoma (“melanocytoma-like
melanoma”) is excellent. However, dogs with maligna t uveal melanoma have significantly shorter
lif spans [105,106]. In human u eal melanoma, despite successful local treatment, up to 25% and 34%
o patients still develop met stases within 5 and 10 years [111]. This situa ion highlights the importance
genetically discriminating benign and malignant forms. Recently, gene express profiles (class 1
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and 2), Ki67 positivity, and loss of chromosome 3 allowed metastasising from non-metastasising human
uveal melanomas to be distinguished [112]. Based on those findings, Malho et al. found that four
of these genes (HTR2B, FXR1, LTA4H, and CDH1) were overexpressed in metastasising canine uveal
melanoma [107]. For one of those, FXR1, immunohistochemical expression was shown to be different
between 10 oral and 10 uveal canine melanoma cases, but the link with the biological behaviour has
still to be determined [113].
Genetic Features and Comparative Aspects
In dogs, there are no genetic somatic or germline alterations identified to date. However, in humans,
frequent somatic activating mutations in GNAQ or GNA11 have been found, leading to the stimulation
of both MAPK and PIK3/AKT pathways [114–116]. Another major gene, BAP1, has been involved
in uveal melanomas, both through somatic alterations and germline variants [117,118]. Moreover,
additional risk polymorphisms have recently been identified in human uveal melanomas [119].
Most recently, Robertson et al. (2017) performed an integrated study of 80 uveal melanoma patients,
and genetic alterations, such as chromosome 3 monosomy/disomy, alterations in EIF1AX, SF3B1, and
BAP-1, together with CNA and the global DNA methylation status, have been demonstrated to carry a
prognostic value [17]. It would be relevant to determine if and how these alterations can discriminate
canine uveal “melanocytoma-like melanoma” from malignant melanoma cases.
8. Innovative Therapies in Human and Canine Melanomas
In human and dogs, complete surgical excision is the first-line treatment of localized
melanomas [38,120,121]. Radiation therapy can improve local control and decrease tumor recurrence
after surgery for mucosal melanoma and is effective to treat some types of human cutaneous melanomas,
like lentigo maligna melanomas [38,120,121]. However, for advanced stage and metastatic diseases,
systemic therapies are essential.
Targeted therapies and immunotherapy have been developed in the last decade and strongly
improved some cancer’s management.
Immunotherapy is a novel treatment modality which consists of treating cancers using and
stimulating the patient’s immune system. It has revolutionized some advanced cancer’s treatment
and outcome, particularly with the development of checkpoint inhibitors targeting cytotoxic T
lymphocytes antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) [122,123]. Those molecules are
mainly expressed on activated T lymphocytes, and the binding to their ligands (several clusters of
differentiation for CTLA-4 and programmed cell death ligands 1 and 2 for PD-1) suppresses T-cell
activity. Upregulation of these inhibitory pathways is observed in many human cancers, particularly
melanoma, and is responsible for the suppression of antitumor immune response, which promotes
cancer immune evasion. Recently, phase III trials showed that anti PD-1 (pembrolizumab, nivolumab)
and anti CTLA-4 (ipilimumab) provided high response rate and durable long-term survival in
responding patients, and they are now part of the first-line treatment in advanced stage and metastatic
melanomas [122,124]. Checkpoint inhibitors, and particularly the combination of nivolumab and
ipilimumab also showed promising results in human mucosal melanomas and should be considered
as a good treatment option for advanced stage and metastatic diseases [121,125]. In canine oncology,
the tumor microenvironment and immune system are less investigated. However, it has been recently
shown that PD-1 and CTLA-4 are significantly overexpressed by peripheral blood T lymphocytes in
cancer-bearing dogs compared with in healthy controls [126,127] and that PD-1 blockade enhances
T-cell activation [127]. Alongside that, PD-L1 was shown to be expressed in many canine cancers,
including oral melanoma [35,128,129]. Those data led to a pilot clinical study in dogs with oral
melanoma, using a canine chimeric monoclonal antibody targeting PD-L1. This drug was safe and well
tolerated in dogs, and 1/7 dogs showed an objective response [130]. These recent data make the dog an
interesting model for translational immunotherapeutic studies that could predict novel drugs efficacy.
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Targeted therapies have also improved outcomes of human metastatic cutaneous melanomas.
Those therapies are used according to the molecular profile of the tumors, and cutaneous melanomas
withBRAFV600 mutations are likely to benefit from the combination of BRAF (vemurafenib, dabrafenib)
and MEK inhibitors (trametinib) [124]. Although typically of short duration, antitumor activity with
KIT inhibitors like imatinib has been observed in mucosal melanoma harboring KIT mutations [121,131].
To date, there are no available targeted therapies against melanoma in dogs. The screening of 21 drugs
on nine canine melanomas cell lines showed that they were not sensible to BRAF and KIT inhibitors
(vemurafenib, masitinib, imatinib), but to bortezomib, a proteasome inhibitor involved in the NF-κB
pathway, that could be a promising targeted therapy [132].
9. Discussion
In this review, we attempt to summarize the present knowledge about the different canine
melanomas in the context of comparative oncology.
The dog appears to be the best-known spontaneous model for human oncology, but there are
other interesting species like horse, cat, or pig, which can develop melanomas, and genetic studies
have been performed in some of these. Advances in our understanding of melanomas have been
facilitated by a range of animal models, which contributed to basic biology, characteristics and roles of
driver genes, and efficiency of targeted therapies. In horses, melanocytic tumors represent up to 19% of
cutaneous tumors and often occur in grey horses [133]. As in dogs, equine melanomas are not thought
to be associated with UV-light exposure. Predisposing alterations have been found in grey horses,
such as a 4.6kb duplication in STX17 [134,135]. In cats, melanocytic neoplasms are a rare entity, the
most frequent site being the eye; uveal melanoma biologic behaviour is quite similar to human uveal
melanoma, because tumors metastasize to internal organs in up to 60% of the cases [38]. However,
common mutations present in human uveal melanoma were not found in the feline counterpart [136].
Recently, melanomas of the oral cavity and the skin have also been described, as a retrospective study,
in 30 cats [137]. Lastly, the MeLiM pig model is a spontaneous model of cutaneous melanoma, with
tumors appearing a few weeks after birth, followed by regression [138]. MeLiM pig genetic data
recently led to the identification of new risk loci [139], but no somatic variants have been identified
to date.
At present, there is an opportunity to use these spontaneous models to define new genes and loci
that influence melanoma risk, to define recurrent molecular alterations that could be drivers, and to
identify therapeutic targets in order to use these data to guide the development of new therapeutic
options and achieve better prognosis in humans.
The great advantage with dogs is the existence of anatomic locations corresponding to those of
human melanomas. Canine and human melanomas share many features, such as clinical presentation,
pathology, and molecular mechanisms. Particularly, canine oral and digital melanomas display an
aggressive behaviour that mimics human mucosal and acral melanomas. However, canine cutaneous
melanomas arising on the hair-bearing skin are not linked to UV exposure, contrary to the majority of
human cutaneous melanoma, and thus might represent relevant models for the rare non-UV-induced
cutaneous melanomas, but not for the classical SSM forms of human cutaneous melanomas.
To date, genetic studies of canine melanomas, mainly based on oral subtypes, showed that their
genomic landscapes are similar to those reported in human non-UV-induced melanomas, with a low
point mutation frequency but a high structural variation burden. Those features, as well as the absence
of UV signature make the dog a good opportunity to study any form of non-UV-induced human
melanomas (cutaneous and noncutaneous).
Another advantage of the dog is the existence of breeds that constitute genetic isolates. Some breeds
are at higher risk to develop melanomas, such as breeds with pigmented skin or mucosa, and are
ideal spontaneous models to screen for pathogenic germline alterations. Moreover, as there is a likely
association between the specific genetic background of breeds and the landscape of somatic mutations,
dog can help to identify relevant alterations in human melanoma subtypes.
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Genetic analyses in dogs such as whole genome sequencing, exome, RNA sequencing, or a CGH
are now routinely performed. Canine sample collection is facilitated by the prevalence of melanoma
in predisposed breeds, and thanks to the efforts of the community. Biological Resource Centres have
been set up, like the French Cani-DNA BRC (http://dog-genetics.genouest.org) or the American Canine
Comparative Oncology Genomics Consortium (CCOGC) (https://ccogc.net/), which have significant
collections of canine melanoma samples.
Those resources and methods can be used to identify therapeutic targets and enhance clinical
trials in pet dogs [35]. This concept of “first-in dogs trials” has been launched by the National Cancer
Institute’s (NCI’s) Comparative Oncology Trials Consortium (COTC; http://ccr.cancer.gov/resources/
cop/COTC.asp), with the aim of answering biological questions that can inform the development
of novel agents for future use in human cancer patients [140,141]. Clinical trials in pet dogs offer
several advantages. First, they are not constrained by traditional Phase I, Phase II, and Phase III trial
designs, and make it possible to address many questions in one study (toxicity, pharmacokinetics,
pharmacodynamics, response etc.) to inform future human clinical studies. Moreover, dogs present
a shorter lifespan and a relatively rapid disease course for most cancers, thus providing the cancer
natural history with earlier outcome measures compared with those from human patients. Since many
canine cancers do not have well-established standards of care, novel agents can be offered to pet dogs
alternatively to conventional therapies, leading to trials benefiting the health of both dogs and humans.
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